As on 27 Jun 2025

Tata India Pharma & Healthcare Fund-Direct Plan-Growth
EquityNAV
₹ 34.75
CAGR (3 Years)
26.42%
AUM (Cr)
₹ 1,231.67
Risk
Very High Risk
About Tata India Pharma & Healthcare Fund-Direct Plan-Growth
To seek long term capital appreciation by investing at least 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sector in India.
Breakdown of this Fund
Chemicals
0.57%
Debt Others
15.74%
Fertilizers
2.21%
Healthcare
52.92%
IT - Software
1.01%
Miscellaneous
3.22%
Pharmaceuticals
96.11%
Retail
1.71%
Market Capitalization
Expense Ratio, Exit Load and Tax
Expense Ratio
0.1
Exit Load
0.50% - If redeemed\switched out within 30 days from the date of allotment. Nil ...
Stamp Duty
0.005% (from July 1st, 2020)
Tax Implication
Returns are taxed at 20%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 12.5% on returns of Rs 1.25 lakh+ in a financial year.